U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07429006) titled 'SAD and MAD Study of AKB-9090 in Healthy Adult Participants' on Feb. 18.
Brief Summary: This is a first-in-human (FIH study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic effects of AKB-9090 in healthy adult participants. The study consists of two stages: Stage 1, a single ascending dose (SAD) phase with five dose cohorts, and Stage 2, a multiple ascending dose (MAD) phase with three dose cohorts. Approximately 40 participants in SAD and 30 in MAD are planned to be enrolled.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
DRUG: AKB-9090
AKB-...